Llwytho...
Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma
Immune checkpoint inhibitors enrich the therapeutic landscape in oesophago-gastric carcinoma. With regard to oesophageal squamous cell carcinoma (ESCC), the selective PD-1 (programmed cell death receptor 1)-inhibitor nivolumab improves disease-free survival in the adjuvant therapy setting (CHECKMATE...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Pharmaceuticals (Basel) |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
MDPI
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7918118/ https://ncbi.nlm.nih.gov/pubmed/33673374 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14020151 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|